Biliary Tract and Non-Small Cell Lung Cancer Treatment      

FOI REFERENCE: 24038   

FOI TITLE: Biliary Tract and Non-Small Cell Lung Cancer Treatment      

FOI DATE: 12^th April 2024  

I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

1.      How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?

A)      Biliary Tract Cancer – 0

B)      Non-Small Cell Lung Cancer – *

2.      How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).

3.      How many unique total patients were treated last month (March 24) with Durvalumab for the following indications?

C)      Biliary Tract Cancer 0

D)      Non-Small Cell Lung Cancer – 7

4.      How many patients received their first treatment in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?

E)      Biliary Tract Cancer – 0

F)      Non-Small Cell Lung Cancer – *

*This relates to low numbers between 1 and 5. Under section 40 (ii) of the Freedom of Information Act 2000, statistically low numbers that potentially identify personal data are required to be withheld because of the Trusts obligation to protect personal data under the Data Protection Act 2018